MedPath

湖北远大天天明制药有限公司

Ownership
-
Established
2003-12-18
Employees
-
Market Cap
-
Website
www.ttmyy.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

64

NMPA:64

Drug Approvals

Tropicamide Phenylephrine Eye Drops

Product Name
复方托吡卡胺滴眼液
Approval Number
国药准字H20253245
Approval Date
Jan 24, 2025
NMPA

Sodium Hyaluronate Eye Drops

Product Name
玻璃酸钠滴眼液
Approval Number
国药准字H20247326
Approval Date
Dec 20, 2024
NMPA

Olopatadine Hydrochloride Eye Drops

Product Name
盐酸奥洛他定滴眼液
Approval Number
国药准字H20249048
Approval Date
Oct 16, 2024
NMPA

Tobramycin Eye Drops

Product Name
妥布霉素滴眼液
Approval Number
国药准字H20247167
Approval Date
Jul 17, 2024
NMPA

Diquafosol Sodium Eye Drops

Product Name
地夸磷索钠滴眼液
Approval Number
国药准字H20243571
Approval Date
Apr 24, 2024
NMPA

Sodium Hyaluronate Eye Drops

Product Name
玻璃酸钠滴眼液
Approval Number
国药准字H20233883
Approval Date
Jun 30, 2023
NMPA

Balanced Salt Solution Irrigating

Product Name
平衡盐溶液(供灌注用)
Approval Number
国药准字H20233750
Approval Date
Jun 21, 2023
NMPA

Moxifloxacin Hydrochloride Eye Drops

Product Name
盐酸莫西沙星滴眼液
Approval Number
国药准字H20233082
Approval Date
Jan 19, 2023
NMPA

Naphazoline Hydrochloride,Chlorphenamine Maleate and Vitamin B12 Eye Drops

Product Name
萘敏维滴眼液
Approval Number
国药准字H20227108
Approval Date
Aug 25, 2022
NMPA

Travoprost Eye Drops

Product Name
曲伏前列素滴眼液
Approval Number
国药准字H20173277
Approval Date
Jun 10, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.